February 6, 2019

The Early Diagnosis of Alzheimer’s Disease: A Patient-centered Conversation with the Care Team

Virtual 2021 European Academy of Neurology (EAN) Congress

Confirming Alzheimer’s Disease Pathology Using Imaging and Fluid Biomarkers

Alessandro Padovani, MD, PhD, discusses the utility and value of biomarker assessments in distinguishing AD, particularly mild cognitive impairment due to AD from other neurodegenerative diseases. He describes the MRI and PET biomarker profiles typically associated with AD, as well as appropriate and inappropriate uses of amyloid PET imaging. Professor Padovani then outlines the role of CSF analysis in the diagnoses of AD, and the predictive value of these biomarkers, before discussing the potential future role of plasma biomarkers as screening tools.

The panel discuss using imaging and fluid biomarkers in their clinical practice and the common challenges with the availability and acceptability of these assessments.

Key Learning Objectives from Biogen’s EAN 2021 Symposium:

  • Address the complexities around diagnosis and management of AD, including how cognitive and functional assessments may support the early diagnosis of AD
  • Gain insights into the use of diagnostic biomarkers and the impact these could have on the patient journey
  • Discuss current and prospective measures that could be undertaken to allow the timely diagnosis and management of individuals with AD, in the context of current healthcare infrastructure

Disclosure: All panelists received honoraria from Biogen for participation in this symposium.

Disclaimer: All of the information discussed today is for informational purposes only; does not constitute medical advice; and is not intended to be a substitute for independent professional medical judgment, advice, diagnosis, or treatment.